Abstract: Objective  To study the efficacy of meglumine cyclic adenosine phosphate combined with sodium creatine phosphate in the treatment of patients with acute myocardial infarction(AMI) and heart failure and its influence on the expression of copeptin(CPP) and neprilysin(sNEP). 
Methods  A total of 134 patients with AMI and heart failure in our hospital were divided into control group(n=67) and observation group(n=67) according to the random number table method. They all received conventional treatment. The control group was treated with meglumine cyclic adenosine monophosphate, and the observation group was treated with meglumine cyclic adenosine monophosphate combined with sodium creatine phosphate. The curative effects, cardiac function, coronary hemodynamics, and changes in serum CPP and NEP of the two groups were compared, and the main adverse cardiovascular events during one-month follow-up were recorded. 
Results  The effective rate of the observation group was higher than that of the control group(P＜0.05). After treatment, the indexes of coronary hemodynamics in the two groups increased, and the systolic peak velocity, diastolic peak velocity and time velocity integral in the observation group were higher than those in the control group(P＜0.05). After treatment, left  ventricular end diastolic volume and left ventricular end systolic volume decreased, while left ventricular ejection fraction increased significantly; the levels of indexes in the observation group were better than those in the control group(P＜0.05). After treatment, the serum CPP and NEP decreased, which were lower in the observation group than in the control group(P＜0.05). The main adverse cardiovascular events were angina pectoris, myocardial infarction and recurrent heart failure within one-month follow-up, and the incidence of major adverse cardiovascular events in the observation group was lower than that in the control group(P＜0.05). 
Conclusion  Meglumine adenosine cyclophosphate combined with creatine phosphate sodium in the treatment of AMI with heart failure has a significant curative effect. It can reduce the serum levels of CPP and NEP, improve coronary hemodynamic status and cardiac function, and reduce the risk of major adverse cardiovascular events, with good safety.

Key words: myocardial infarction, heart failure, creatine phosphate sodium